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Abstract Diagnostic tools for invasive fungal infections have
continuously improved within the last decades. Nowadays,
cultural methods, antigen testing, and molecular tests, such
as polymerase chain reaction, are widely used. These
methods, however, are accompanied with different limitations
as various availability, various turnaround time or high costs.
A new generation of point-of-care test has shown promising
results in various studies and may overcome some of these
limitations. We therefore reviewed the literature for the most
promising new point-of-care tests for invasive aspergillosis
(Aspergillus-specific lateral-flow device test, Aspergillus
proximity ligation antigen assay), cryptococcosis (cryptococ-
cal lateral-flow assay), and for histoplasmosis (loop-mediated
isothermal amplification assay).
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Introduction
Invasive fungal infections (IFIs) are a major cause of morbid-
ity and mortality in immunocompromised patients [1–3]. Host
factors such as severe and prolonged neutropenia, allogeneic
stem cell transplantation, prolonged use of corticosteroids,
prolonged hospitalization at an intensive care unit (ICU),
and receipt of recognized T cell immunosuppressants may
predispose patients for developing IFI [1, 4].
IFIs have a wide spectrum of clinical presentations, and
diagnoses mostly rely on laboratory-based results. Culture-
based methods are valuable but limited by time to results,
and due to the relatively insensitive for the detection of fungal
pathogens [5, 6]. Matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry (MALDI-TOFMS) is a very
promising development for identification of culture isolates.
MALDI-TOF testing is simple to perform, accurate, can tech-
nically identify nearly every organism, and may even detect
resistance [5]. Nevertheless, impact of MALDI-TOF testing
on early diagnosis and treatment of IFIs is limited, as a posi-
tive culture result is a prerequisite for that method. Currently,
amplification-based assays are under development that may
ultimately replace culture-based tests in the laboratory [5].
Amplification-based assays may provide results to the labora-
tory within 20 min to 5 h. New multiplex polymerase chain
reactions (PCRs) are often able to detect a selection of multi-
ple pathogens in a single session [5]. However, currently
available amplification assays are mostly limited by relatively
high costs, inconsistent performance in terms of sensitivities
and specificities, and lack of standardization. Loop-mediated
isothermal amplification (LAMP) is a cheaper and more sim-
ple technique than traditional PCR, and therefore an advanta-
geous alternative, providing results to the laboratory in less
than 60 min [5]. Thus, LAMP for diagnosis of histoplasmosis
will be discussed in this review.
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Besides molecular diagnostic tools, antigen-based tests are
widely used in clinical routine for IFI diagnosis. They are
much faster compared to culture and able to provide quantita-
tive results to the clinician optimally within a day [5].
Depending on the setting, however, time to results may vary,
depending on factors such as transport to the laboratory that
performs the test. In contrast, qualitative antigen-based assays
may allow point-of-care (POC) diagnosis of IFI within mi-
nutes, frankly on the bedside. Antigen-based POC tests are
currently available for Aspergillus spp. and Cryptococcus
spp. [5], and both will be discussed in this review.
POC Diagnosis of Invasive Aspergillosis
Aspergillus spp. and other molds are the major cause of IFIs
among patients with underlying hematological malignancies
[3, 7]. Successful management of invasive aspergillosis (IA)
in these critically ill patients requires early and reliable diagno-
sis and rapid initiation of appropriate antifungal therapy. A
study analyzing autopsy data over two decades has shown in
2013 that rates of premortem diagnosis of IA have increased
over the last decade. While 84 % of the IFIs were diagnosed
postmortem in the first 5 years of the study, the rate decreased
to 49 % in the last 4 years of the study [8]. Most likely reasons
for an ongoing increase of premortem IA diagnoses are the
introduction of antigen testing in serum and bronchoalveolar
lavage fluid (BALF) specimens [9, 10]. Galactomannan anti-
gen (GM) testing is currently considered the gold standard
when it comes to biomarkers for IA diagnosis. Several studies
have evaluated the performance of GM detection in different
specimen (BALF, blood, urine, cerebrospinal fluid) and pro-
posed its utility in daily clinical routine. GM determination,
which is performed using the Platelia™Aspergillus enzyme im-
munoassay (Bio-Rad, France), however, has some limitations.
First, the variable turnaround time within different centers de-
pending on the amount of specimen sent in for GM determina-
tion. The Platelia™Aspergillus enzyme immunoassay (Bio-
Rad, France), approved from the FDA as an adjunctive test
for IA diagnosis, is performed on a 96-well plate. Second,
GM determination requires specially equipped laboratories
and trained staff that is not available in all centers. Third, the
GM ELISA also detects antigens produced by Geotrichum
capitatum and cross-reacts with other opportunistic fungal
pathogens like Histoplasma spp. and may with Cryptococcus
neoformans [11–13]. Qualitative POC assays for GM detection
are currently in development and may be promising for the
future, once developed, evaluated, and approved.
Aspergillus-Specific Lateral-Flow Device Test
The POC Aspergillus-specific lateral-flow device (LFD) test
has been developed more than 5 years ago and evaluated in a
number of studies. The LFD is an immunochromatographic
assay using a mouse monoclonal antibody, JF5, which binds
to an extracellular glycoprotein antigen from Aspergillus spp.,
only secreted during active growth. Minimal required training,
simple handling by using BALF samples without any pretreat-
ment, no need for specially equipped laboratories, rapid avail-
ability of test results within 15 min, and low costs are the
major advantages of the LFD. In case of serum testing, sam-
ples need to be pretreated by heating, centrifugation, and
adding a buffer solution according to the manufacturer’s rec-
ommendations [14, 15]. Results are read by eye after 15-min
incubation time and are interpreted depending on the intensity
of the test line as negative (−) or weak (+) to strong (+++)
positive. Even though the results are read by the naked eye and
one may argue that this may lead to poor reproducibility,
Wiederhold and colleagues performed a study using a guinea
pig model of IA and tested serum and BALF samples in two
independent laboratories. Thirty-two of 33 (97 %) serum sam-
ples and 26/33 (79 %) BALF samples were in agreement
within these two laboratories, indicating a good reproducibil-
ity [16]. Cross-reactivities are also rare with the LFD. Only
cross-reactions with Penicillium spp. are described in the orig-
inal publication [15]. Since these data were published, interest
in this new POC test has increased and several clinical studies
evaluated the clinical performance of the LFD test in various
patient cohorts and different specimen.
In one of the first in vivo studies evaluating BALF samples
from 29 patients with hematological malignancies, the LFD
yielded sensitivity of 100 % and a specificity of 81.8 % for
diagnosis of IA. Four samples yielded false-positive results,
but all of them were interpreted as weak positive only [17]. A
further study on BALF-LFD in hematological patients also
yielded a 100 % sensitivity and a specificity of 83 % [18].
Even though this study was limited by a very small sample size
of hematological patients (n=7), results were similar to the
prior mentioned study. The largest study evaluating the perfor-
mance of the BALF-LFD test in hematological malignancy
patients was published in 2015, and 95 BALF samples were
analyzed from 72 prospectively enrolled patients of whom 27
patients (30 samples) had probable IA [19]. Per patient sensi-
tivity was lower compared to the former studies (71 %), but
specificity was similar (76 %). This may partly explained due
to the fact that all patients with false-negative results within the
last study were on antifungal prophylaxis/treatment at the time
of bronchoscopy. Mold active prophylaxis/treatment may
cause a significant decrease of BALF-LFD sensitivity as shown
in a recently published study. This retrospective analysis
yielded BALF-LFD sensitivity of 86 % in patients not receiv-
ing mold-active agents versus 52 % in patients receiving mold-
active agents (p=0.006) [20]. In addition, in most studies per-
formed on BALF-LFD, no or little information is given on
pretreatment of BALF samples prior to testing. This, however,
is of particular interest as pretreatment with dithiothreitol (a
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commonly used mucolytic agent for respiratory tract samples)
containing liquefying agents significantly alters LFD test line
intensities and reduces GM levels [21]. In another recently
published study by Johnson et al., the performance of real-
time PCR, LFD, and GM in BALF samples obtained from
patients at risk for IA was evaluated and showed that PCR
and LFD had perfect sensitivity of 100 % compared to
87.5 % sensitivity for GM detection [22]. Specificity was
slightly lower for both, PCR and LFD, when calculated for
each test (87 and 80 %, respectively) but superior to specificity
of GM detection with a specificity 66.6 %. PCR and LFD
results showed a nearly perfect agreement with a kappa coeffi-
cient value of 0.93. Thus, combination of PCR and LFD did not
result in an increase of specificity (85.7 %), showing the high
potential of the LFD test.
Similar to GM, the LFD may also be performed in serum
samples. Results from studies investigating the performance
of the LFD when using serum samples, however, showed less
promising results compared to BALF testing. This may be in
part explained due to the fact that systemic antifungal
prophylaxes/therapy may have a stronger influence on serum
samples compared to BALF samples [23] which was also
shown for GM detection [24]. Held and colleagues reported
a sensitivity and specificity of about 40 and 86.8 % for serum-
LFD testing in hematological stem cell transplant (HSCT)
recipients when only one positive LFD was required for IA
diagnoses and a sensitivity of only 20 % and specificity of
97.8 % when two consecutive positive LFD samples were
required for diagnosis [25]. Positive samples, however, need
to be interpreted in context with clinical signs and symptoms
and should trigger further investigations as demonstrated by
White and colleagues, who reported a poor positive predictive
value (PPV) of 67 % when using serum-LFD results for IA
diagnosis but a remarkable increase of the PPV when using
LFD in combination with either PCR (100 %) or GM (80 %)
for diagnosis [26].
As seen with GM, BALF samples seem to be the most
promising when using the LFD test for IA diagnosis in
nonneutropenic patients, in particular patient collectives out-
side of the hematological malignancy setting. A number of
studies on BALF-LFD performance in patient cohorts besides
hemato-oncological patients have been published, revealing
consistent and promising results of the test. In solid organ
transplant (SOT) recipients, for example, sensitivities between
91 and 100 % as well as specificities of 80–83 % were report-
ed [17, 27]. Similar performance could be observed for ICU
patients with sensitivity of 80 % and specificity of 81 % [28].
The high negative predictive value of 96 % in this study may
be used in clinical routine to rapidly rule out suspected IA in
ICU patients and may withhold antifungal therapy. This is of
particular interest in ICU patients as up to two thirds of ICU
patients receiving antifungal agents without evidence for IFIs
[29]. Performance of BALF-LFD was also evaluated in
patients with underlying pulmonary disease [6]. Sensitivity
for IA diagnosis reached 77 % and specificity 92 %. Thus,
the LFD showed a significant higher sensitivity compared to
mycological culture (77 vs 29%) and even a higher specificity
compared to BALF-GM determination (92 vs 81 %). In con-
trast, data on the performance of serum LFD testing in
nonneutropenic patients, like ICU patients or SOT recipients,
are lacking to date.
In conclusion, the LFD test seems to be a promising POC
test for IA diagnosis as it showed good performance in clinical
studies and overcomes some of the limitations given with GM
determination as variable turnaround time, availability, or
cross-reactions. Performances of the LFD test in the different
patient cohorts as well as in different specimen (using pub-
lished studies) are displayed in Tables 1 and 2.
Proximity Ligation Assay as a Diagnostic Technique
for Invasive Aspergillosis
Proximity ligation assays (PLA) are very specific antibody-
based tests with high sensitivity and therefore a valuable di-
agnostic option. Johnson et al. [30] successfully designed a
PLA for detecting a Aspergillusmannoprotein. They used the
monoclonal antibody JF5, which is the same antibody used
with the Aspergillus LFD test, for targeting a Aspergillus-spe-
cific extracellular mannoprotein. In their study, Aspergillus
culture filtrate was gained and spiked to saline and serum
[30]. PLA, GM detection by using the Platelia™Aspergillus
enzyme immunoassay (Bio-Rad, France), and the LFD were
performed with these samples. The results of the PLA showed
a 10- to 100-fold higher sensitivity compared to the GM assay
and a 1000-fold higher sensitivity compared to the LFD assay.
Furthermore, three BALF samples were tested with the PLA
in cases with probable IA and positive GM assay, LFD, and
PCR. The PLA results were coherently positive in all three
cases [30]. In addition, the PLA assay also had a high speci-
ficity and showed no cross-reactivity when tested with culture
filtrates of other fungal species (i.e., Candida, Mucor,
Fusarium). In conclusion, the Aspergillus PLA developed by
Johnson et al. seems to be highly sensitive and specific and
warrants future investigation in a higher number of clinical
samples.
POC Diagnosis of Cryptococcosis
Cryptococcal meningitis is a life-threatening opportunistic fun-
gal infection caused by Cryptococcus spp., primarily by the
pathogenic species Cryptococcus neoformans var. grubii and
var. neoformans and Cryptococcus gattii. Cryptococcosis oc-
curs mostly HIV related [31], but increasing incidence has also
been reported in SOT recipients. Overall, cryptococcal menin-
gitis is estimated to affect nearly a million patients per year,
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with more than 600,000 deaths predominantly in developing
resource-limited countries [32]. To reduce the high mortality
rate, which reaches 12 % in industrialized countries like the
USA [33] and almost 90 % in sub-Saharan and South Africa
[34, 35], rapid and reliable diagnostic tools for detection of the
basidiomycetous fungi are of utmost importance. Mycological
culture is still considered the gold standard but is limited long
turnaround time. In addition, appropriately equipped laborato-
ries as well as technical expertise are required for culturing
cerebrospinal fluid (CSF), which both are often not available
in resource-limited countries. Hence, diagnosis of cryptococ-
cosis mostly relied on direct microscopy of CSF, though this is
characterized by poor sensitivity. Therefore, detection of cryp-
tococcal antigen (CrAg), a component of the cryptococcal
polysaccharide capsule glucoronoxymannan (GXM), has be-
come increasingly important. To date, two main methods for
detection of the CrAg exist. On the one hand, latex agglutina-
tion (LA) and on the other hand the enzyme immunoassay
(EIA). Both methods are highly sensitive and specific, and less
time-intensive compared to culture or microscopy [36].
However, LA as well as EIA have limitations. First, they re-
quire laboratory infrastructure and skilled technicians and
second, false-negative results and prozone effects (= false-
negative results due to very high concentrations of particular
analyte in immunoassays) were well known [37].
Cryptococcal Antigen Lateral-Flow Assay
The CrAg lateral-flow assay (LFA) is a POC test for the detec-
tion of CrAg, which was developed by Immy Inc. (Norman,
OK) in 2009. The CrAg LFA satisfies all requirements for a
POC test: low costs (approximately 2$ per strip in resource
limited settings), excellent test performance, easy to use and
rapid test results (available in 10 min) [38]. Moreover, the
CrAg LFA is temperature stable and cross-reactions with other
fungi are rare. For testing, 40 μl of body fluid (serum, plasma,
urine, and CSF) without pretreatment are applied to a reservoir
of the LFA test strip. If GXM is present, the anti-GXM mono-
clonal antibodies—the test uses two monoclonal antibodies
and can recognize all four GXM serotypes (A–D)—forms a
visible line. The handling of the test and the interpretation of
the test line result have been well demonstrated in publications
[39, 40]. In one study, sensitivity of the serum CrAg LFA of
100 % and a specificity of 99.8 % was reported, when using
Table 1 Aspergillus LFD
performance in BALF and serum
in various patient cohorts
Study Risk group Sample size
(n of patients)
Specimen Sensitivity Specificity Reference
Hoenigl 2012 HM 29 BALF 100 81.8 [17]
Miceli 2015 HM 7 BALF 100 83 [18]
Prattes 2015 HM 72 BALF 71 76 [19]
Johnson 2015 HM and non-HM 32 BALF 100 80 [22]
Hoenigl 2012 SOT 10 BALF 100 80 [17]
Willinger 2014 SOT 47 BALF 91 83 [27]
Eigl 2015 ICU 133 BALF 80 81 [28]
Prattes 2014 Respiratory
Disease
221 BALF 77 92 [6]
Held 2013 HSCT 101 Serum 40a 86.8a [25]
20b 97.8b
White 2013 HM 103 Serum 81.8a 84.8a [26]
59.1b 98b
HM hematological patients, SOT solid organ transplant recipients, ICU intensive care unit, HSCT hematological
stem cell transplantation recipients, BALF bronchoalveolar lavage fluid
a Single testing = a minimum of one positive LFD results is required for diagnosis
b Multiple testing = a minimum of two or more positive LFD results are required for diagnosis
Table 2 Performance of the
BALFAspergillus LFD for
probable/proven invasive
pulmonary aspergillosis versus no
evidence for invasive pulmonary
aspergillosis (per BALF sample)
in different patient cohorts
Patient group Sensitivity Specificity PPV NPV
Solid organ transplantation 94 % (15/16) 92 % (89/97) 65 % (15/23) 99 % (89/90)
Intensive care unit 79 % (26/33) 85 % (176/206) 57 % (26/46) 96 % (176/183)
Respiratory diseases 77 % (24/31) 92 % (195/211) 60 % (24/40) 97 % (195/202)
Hematological malignancies 65 % (30/47) 89 % (88/99) 73 % (30/41) 84 % (88/105)
Data derived from published studies: [6, 14, 17–20, 27, 28, 66]
PPV positive predictive value, NPV negative predictive value
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serum LA test as gold standard [41]. In the same year, another
study also reported a 100% sensitivity of the serum CrAg LFA
which was higher than the 91 % found for serum LA.
Importantly, this study included only very few patients with
HIV infection, indicating the potential diagnostic value of the
CrAg LFA also for other populations with cryptococcal disease
[42]. Other studies comparing the CrAg LFA to other CrAg
based tests in low-income countries show similar results: sen-
sitivities of 95.6–100% and specificities of 96.9–99.5 % when
using serum specimens [43, 44], and sensitivities of 80–100 %
and specificities of 73.8–91.5 % when using urine samples
(also depending on the diluents) [45]. The reliable performance
of the CrAg LFAwas confirmed in studies evaluating its per-
formance compared to culture or composite reference standard:
sensitivities of 98.3–100 % in serum samples, 92–98 % in
urine specimens, and 86.1–100 % in CSF samples [44,
46–48]. Since 2011, the World Health Organization (WHO)
has added the CrAg LFA to the LA test as preferred method
for diagnosis of cryptococcal disease [49].
To summarize, the CrAg LFA has several advantages: mul-
tiple samples can be run simultaneously, cost-effective, and do
not need electricity, specially equipped laboratory, or skilled
technicians. Importantly, CrAg LFA is not useful to check
treatment response, as the clearance of CrAg is a slow and
also independent process that devitalize the yeast [50, 51].
During effective antifungal therapy, CrAg LFA titers may
therefore remain elevated [52, 53].
CrAg has been confirmed as a reliable predictor of devel-
opment of cryptococcal disease after initiating antiretroviral
therapy (ART), and even mortality [47, 54–56]. Twenty to
30 % of patients in resource-poor countries present crypto-
coccal meningitis within 3 months after initiating ART [57,
58]. French et al. reported that CrAg may be detectable as
early as 100 days before the beginning of symptomatic cryp-
tococcal disease [59]. Therefore, the WHO recommends
routine serum or plasma CrAg screening in HIV-positive
patients without ART and a CD4 cell count <100 cells/
mm3 [49]. With regard to the role of the test in preemptive
screening, one important questions remains to be answered:
how to proceed with patients that do not have symptoms of
cryptococcal meningitis but a positive CrAg result? While
the WHO recommends a Bscreen and treat asymptomatic
positives with fluconazole^ strategy, future studies are need-
ed to answer this question.
In conclusion, the diagnostic accuracy of CrAg has been
evaluated in multiple studies in resource-rich and resource-
limited countries and showed excellent sensitivity and spec-
ificity on serum, plasma, urine [44, 48], and CSF samples
[47]. A positive CrAg allows the treating physician to initi-
ate appropriate antifungal therapy without delay and may
additionally predict mortality risk. CrAg LFA may also play
a future role in preemptive screening, consequently in cost
reduction and outcome improvement [45, 60–62]. This POC
test, therefore, clearly has the potential to markedly improve
the early diagnosis of cryptococcosis.
Advancement in the Diagnosis of Histoplasmosis
Histoplasmosis and especially progressive disseminated his-
toplasmosis (PDH) in patients with immunodeficiency is
caused by Histoplasma capsulatum, a fungus endemic in
North and South America, Africa, Asia, and Australia [63].
Diagnosis is challenging; in particular, the current alternatives
to culture diagnostics are too expensive for resource-
challenged countries [64]. Rapid and reliable assays are im-
portant for the treatment of PDH, asmortality rate increases up
to 42% when therapy is delayed and up to 95 %when PDH is
misdiagnosed [64]. The diagnostic process is also complicated
as symptoms of PDH are unspecific and similar to infections
withmycobacteria or leishmania [65]. The currently available
diagnostics for H. capsulatum comprise detection by culture,
which can be enhanced by culture identification with the
AccuProbe® test. The main problem with this method is that
culturing H. capsulatum can take a few weeks, and the
AccuProbe® test is expensive [64]. As an alternative, there
are different PCR-based assays available. However, these are
also expensive and not well evaluated yet [65].
Scheel et al. [64] conducted a pilot study in which they
developed a LAMP assay and evaluated its sensitivity and
specificity in comparison to the PCR-based assays. LAMP is
an alternative method for DNA amplification using a different
polymerase (Bst) as used for traditional PCR (Taq). Bst-poly-
merase is cheaper and more robust than Taq. LAMP also re-
quires less expensive equipment compared to traditional PCR.
In their study, Scheel et al. [64] chose the Hcp100-locus of H.
capsulatum for amplification and designed a LAMP primer, as
that locus has only few similarities to related microorganisms,
and there are no any known mutations that may lead to false
negativity. Furthermore, they collected different geographic
subspecies of H. capsulatum isolates (n=91), extracted the
DNA, and proceeded with PCR and LAMP to compare the
sensitivities of these two assays, and to evaluate the limit of
necessary genomes for the LAMP assay to become positive
(limit of detection (LOD)). In addition, Scheel et al. [64] col-
lected urine samples from healthy persons (n=10) as well as
from HIV patients with PDH (n=6; proven by clinical symp-
toms, positive antigen detection and positive culture with urine
samples), where they compared sensitivity and specificity of
PCR and LAMP. The LOD was noted to be a median of 6
genomes (from 1 to 30 genomes, strain-dependent), and 10-
fold lower than the LOD of PCR.Within an incubation time of
1.5 h, no cross-reactivity could be recognized when the de-
signed LAMP primer had been used for assays with other
fungi, M. tuberculosis or human DNA, which means a speci-
ficity of 100 % in this pilot study. Coherent to these findings,
there was no false-positive LAMP assay when testing the urine
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samples of the healthy persons. LAMP was only able to detect
H. capsulatum DNA in four of the six urine samples (67 %),
which was still superior to the simultaneously conducted PCR
assays, and was not able to show any positive test result when
testing the urine samples. In conclusion, Scheel et al. [64]
showed that H. capsulatum DNA can be detected from cul-
tured isolates as well as from urine samples of patients with
PDH when using their LAMP assay. As the search for a POC
test forH. capsulatum continues, the study presents interesting
findings that may advance diagnosis in the meantime.
Conclusion
Important advances have been made during the last years in
particular with regard to POC diagnosis of cryptococcosis but
also for IA. The CrAg LFD not only has excellent sensitivity
over all four serotypes of Cryptococcus but is also FDA ap-
proved and commercially available; commercial availability
of the Aspergillus LFD is still pending. While LAMP may
offer significant advancement in the diagnosis of histoplasmo-
sis, the search for reliable POC tests for other fungi continues.
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